Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will release earnings results for the first quarter, after the closing bell on Monday, Nov. 3.
Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.58 per share, up from $4.38 per share in the year-ago period. The consensus estimate for Vertex Pharmaceuticals' quarterly revenue is $3.06 billion, compared to $2.77 billion a year earlier, according to data from Benzinga Pro.
On Aug. 4, Vertex Pharmaceuticals posted better-than-expected earnings for the second quarter.
Vertex Pharmaceuticals shares rose 1.4% to close at $425.57 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.
- Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and cut the price target from $439 to $438 on Oct. 10, 2025. This analyst has an accuracy rate of 67%.
- JP Morgan analyst Jessica Fye maintained an Overweight rating and boosted the price target from $517 to $530 on Oct. 8, 2025. This analyst has an accuracy rate of 72%.
- Citigroup analyst Geoff Meacham maintained a Buy rating and raised the price target from $550 to $575 on Oct. 2, 2025. This analyst has an accuracy rate of 72%.
- Leerink Partners analyst David Risinger upgraded the stock from Market Perform to Outperform and cut the price target from $458 to $456 on Sept. 25, 2025. This analyst has an accuracy rate of 72%.
- Evercore ISI Group analyst Lisa Bayko maintained an Outperform rating and cut the price target from $510 to $475 on Sept. 11, 2025. This analyst has an accuracy rate of 71%.
Considering buying VRTX stock? Here’s what analysts think:
Read This Next:
Photo via Shutterstock
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
